ClinicalTrials.gg

Program

antihemophilic factor, human recombinant

Also written as “Antihemophilic factor, recombinant, manufactured protein-free”, “Recombinant Factor VIII (BAY81-8973)” and “ADVATE”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 3 companies.

Furthest: phase 4, since Oct 21, 200516 company-led studies, 1 open or runningNext primary completion: Nov 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda101 open or runningphase 4since Oct 21, 2005Sep 8, 2005Nov 25, 2027phase 3 · NCT07129343
Bayer50 open or runningphase 4since Sep 4, 2020Dec 8, 2009none ahead
Novo Nordisk10 open or runningphase 1since Feb 4, 2009Feb 4, 2009none ahead

Also a collaborator on its studies: Takeda Development Center Americas and Baxter Innovations.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Sep 8, 2005.

  1. Oct 21, 2005Phase 4 study in Hemophilia ATakeda · NCT00243386 · 82 enrolled · United States, Austria, Czechia and more
  2. Feb 9, 2006Phase 4 study in Hemophilia ATakeda · NCT00289536 · 38 enrolled · United States
  3. Feb 4, 2009Novo Nordisk’s first study: phase 1 study in Hemophilia ANew to Novo NordiskNovo Nordisk · NCT00837356 · 23 enrolled · Germany, Israel, Italy and more
  4. Aug 4, 2009Phase 1 study in Hemophilia ATakeda · NCT00952822 · 52 enrolled · United States
  5. Dec 8, 2009Bayer’s first study: phase 3 study in Blood Coagulation DisordersNew to BayerBayer · NCT01029340 · 74 enrolled · United States, Argentina, Austria and more
  6. Nov 2, 2010Phase 3 study in Hemophilia ABayer · NCT01233258 · 80 enrolled · United States, Argentina, China and more
  7. Feb 18, 2011Phase 3 study in Hemophilia ABayer · NCT01311648 · 94 enrolled · United States, Argentina, Bulgaria and more
  8. Jun 17, 2011Phase 3 study in Hemophilia ATakeda · NCT01376700 · 22 enrolled · United States, Austria, Bulgaria and more
  9. Jun 24, 2015Phase 1 study in Hemophilia ABayer · NCT02483208 · 18 enrolled · Bulgaria
  10. Oct 12, 2016Phase 3 study in von Willebrand DiseasesTakeda · NCT02932618 · 47 enrolled · United States, Austria, Belgium and more
  11. Sep 4, 2020Phase 4 study in Hemophilia ABayer · NCT04565236 · 45 enrolled · China
  12. Jul 29, 2021Phase 4 study in Hemophilia ATakeda · NCT04985682 · 50 enrolled · India
  13. Aug 12, 2025Phase 3 study in von Willebrand DiseasesTakeda · NCT07129343 · 20 planned · China
  14. Oct 21, 2026Primary completion moved from 2027-09-30 to 2028-03-31Date moved laterno phase · +6 months · NCT07446010

Ahead

  1. Nov 25, 2027Primary completion: phase 3 study in von Willebrand DiseasesTakeda · NCT07129343

TargetBeta

F8 →read by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
efanesoctocog alfaruleSanofiphase 412
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07129343von Willebrand Diseases · China3RecruitingTakedaNov 25, 202720
NCT04985682Hemophilia A · India4CompletedTakedaFeb 10, 202350
NCT04565236Hemophilia A · China4CompletedBayerMar 15, 202445
NCT02932618von Willebrand Diseases · United States, Austria, Belgium and more3CompletedTakedaApr 17, 202647
NCT02483208Hemophilia A · Bulgaria1CompletedBayerJul 201518
NCT01376700Hemophilia A · United States, Austria, Bulgaria and more3TerminatedTakedaNov 16, 201222
NCT01311648Hemophilia A · United States, Argentina, Bulgaria and more3CompletedBayerSep 9, 201994
NCT01233258Hemophilia A · United States, Argentina, China and more3CompletedBayerDec 201280
NCT01029340Blood Coagulation Disorders · United States, Argentina, Austria and more3CompletedBayerJun 201274
NCT00952822Hemophilia A · United States1CompletedTakedaOct 23, 200952
NCT00837356Hemophilia A · Germany, Israel, Italy and more1CompletedNovo NordiskOct 200923
NCT00289536Hemophilia A · United States4CompletedTakedaApr 1, 200738
NCT00243386Hemophilia A · United States, Austria, Czechia and more4CompletedTakedaJun 16, 201082
NCT00157105Hemophilia A · United States3CompletedTakedaAug 3, 200459
NCT00157053Hemophilia A · United States, Austria, Belgium and more3CompletedTakedaAug 3, 200482
NCT00157040Hemophilia A · United States, Canada, Puerto Rico3CompletedTakedaJan 4, 200550

How it is read

Names in the registry

  • “Antihemophilic factor, recombinant, manufactured protein-free”, 8 entries
  • “Recombinant Factor VIII (BAY81-8973)”, 3 entries
  • “ADVATE”, 2 entries
  • “Recombinant Factor VIII (Kovaltry, BAY81-8973)”, 2 entries
  • “Antihemophilic Factor (Recombinant)”, 1 entry

Codes read as this program: BAY818973.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.